Core Viewpoint - Nxera Pharma Co. Ltd will announce its earnings results and operational highlights for the year ended 31 December 2025 on 13 February 2026, with a live webinar presentation featuring key executives [1][2]. Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines to address unmet patient needs in Japan and globally [2]. - The company has established a new-generation commercial business in Japan, aiming to develop and commercialize innovative medicines for a large and growing market in the APAC region [2]. - Nxera Pharma utilizes its unique NxWave™ GPCR structure-based drug discovery platform to advance an extensive pipeline, both internally and in collaboration with leading pharmaceutical and biotech companies [2]. - The company operates in key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [2]. Webinar Details - The upcoming webinar is open to existing and potential investors, as well as sell-side and buy-side analysts, featuring a presentation followed by a Q&A session [2]. - Presentation slides will be available on the investor section of the company's homepage by 4:30 pm JST on 13 February 2026 [2].

Core Insights - Nxera Pharma's President & CEO, Chris Cargill, will participate in a 'Fireside Chat' at the Jefferies London Healthcare Conference on 17 November 2025, discussing the company's strategy, recent progress, and upcoming milestones [1] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines for patients with unmet needs in Japan and globally [4] - The company has established a new-generation commercial business in Japan, aiming to develop and commercialize innovative medicines for a large and growing market in the APAC region [4] Pipeline and Innovation - Nxera Pharma is advancing a pipeline of over 30 active programs, utilizing its unique NxWave™ discovery platform, targeting major unmet needs in obesity, metabolic disorders, neurology/neuropsychiatry, and immunology/inflammation [5] - The pipeline includes potentially first- and best-in-class candidates, indicating a strong focus on innovation and addressing critical health issues [5] Workforce and Global Presence - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, highlighting its international footprint [6]